

Enhance the Quality of Care for Your Symptomatic and Asymptomatic Patients

By Enabling Single-Visit Test and Treat with the binx io CT/NG Assay

"Providers might consider **opt-out chlamydia and gonorrhea screening** (i.e., the patient is notified that testing will be performed unless the patient declines, regardless of reported sexual activity) for adolescent and young adult females during clinical encounters. Cost-effectiveness analyses indicate that opt-out chlamydia screening among adolescent and young adult females might substantially increase screening, be cost-saving, and identify infections among patients who do not disclose sexual behavior."*

2021 CDC STI Treatment Guidelines



Drive Revenue and Increase Profits for Your Practice with the binx *io* CT/NG Assay

Bring the Power of High-Quality Diagnostic Testing to Your Clinic

Stop sending patient samples and your profit margin to reference labs. With the binx *io* CT/NG Assay, you can conduct all your CT/NG testing in clinic.

Established Guidelines for CT/NG Testing Combined with Reimbursement Enable a New Clinic Revenue Stream



Billable with established CPT codes Chlamydia Test 87491

Gonorrhea Test 87591 Infectious Agent, Multiple Organisms
87801

Proper coding can vary by payor and clinic type. Options include **87801** with or without the CLIA-waiver modifier QW, or **87491** and **87591**.

For more information or to order the binx *io* instrument and binx *io* CT/NG Assay, contact your binx sales representative or sales@mybinxhealth.com

binx *io* Instrument Catalog number: 3.001.001

binx *io* CT/NG Assay Catalog number: 1.002.150 Male Urine Specimen Collection Kit Catalog number: 5.002.050

Vaginal Swab Specimen Collection Kit Catalog number: 5.012.050

sales@mybinxhealth.com | 1-844-MYBINX-1 (1-844-692-4691) | binx-io.com

